Anticancer activity of a ceramide analog containing a disulfide linkage.

R. Bittman,Zaiguo Li,P. Samadder,G. Arthur

DOI: https://doi.org/10.1016/J.CANLET.2006.10.026

IF: 9.756

2007-06-18

Cancer Letters

Abstract:

What problem does this paper attempt to address?

Maternal lung growth in surgically reduced litter size pregnancy.

E. E. Faridy,S. Bucher

DOI: https://doi.org/10.1016/0034-5687(88)90005-9

1988-05-01

Respiration Physiology

Abstract:
Cellular and molecular mechanisms of aspartoacylase and its role in Canavan disease

Martin Grønbæk-Thygesen,Rasmus Hartmann-Petersen

DOI: https://doi.org/10.1186/s13578-024-01224-6

2024-04-07

Cell & Bioscience

Abstract:Canavan disease is an autosomal recessive and lethal neurological disorder, characterized by the spongy degeneration of the white matter in the brain. The disease is caused by a deficiency of the cytosolic aspartoacylase (ASPA) enzyme, which catalyzes the hydrolysis of N-acetyl-aspartate (NAA), an abundant brain metabolite, into aspartate and acetate. On the physiological level, the mechanism of pathogenicity remains somewhat obscure, with multiple, not mutually exclusive, suggested hypotheses. At the molecular level, recent studies have shown that most disease linked ASPA gene variants lead to a structural destabilization and subsequent proteasomal degradation of the ASPA protein variants, and accordingly Canavan disease should in general be considered a protein misfolding disorder. Here, we comprehensively summarize the molecular and cell biology of ASPA, with a particular focus on disease-linked gene variants and the pathophysiology of Canavan disease. We highlight the importance of high-throughput technologies and computational prediction tools for making genotype–phenotype predictions as we await the results of ongoing trials with gene therapy for Canavan disease.

biochemistry & molecular biology
Comparative computational assessment of the pathogenicity of mutations in the Aspartoacylase enzyme

C George Priya Doss,Hatem Zayed

DOI: https://doi.org/10.1007/s11011-017-0090-5

Abstract:Aspartoacylase (ASPA) is a zinc-dependent abundant enzyme in the brain, which catalyzes the conversion of N-acetyl aspartate (NAA) into acetate and aspartate. Mutations in the ASPA gene are associated with the development of Canavan disease (CD), leading to the deficiency of ASPA activity. Patients with CD were characterized by degeneration of the white matter of the brain. We reported earlier on two patients with severe form of CD that both had two novel missense mutations in the ASPA: c.427 A > G; p. I143V and c.557 T > A; p. V186D (Zaki et al. 2017a), patient 1 harbored both mutations (p.I143V and p.V186D) in a heterozygous form together with four other mutations, and patient 2 had both mutations in homozygous form. Wijayasinghe et al. (2014) crystallized the 3D structures of four different ASPA mutants (p.K213E, p.Y231C, p.E285A, and p.F295S). In this study, we used in silico prediction methods and molecular dynamics simulation (MDS) to understand the structural impact of all these mutations. Moreover, we used molecular docking (MD) to investigate the binding patterns of the NAA substrate to the native and mutant proteins. Among the mutations, p.E285A (crystallized mutant) was predicted to be the most deleterious for the protein function and the least deleteriousness mutant was the p.I143V (novel mutant). Among the novel mutations, p.V186D was observed to be disruptive for both the zinc binding and NAA binding than the p.I143V. This study provides practical insights on the effect of these mutations on the ASPA function and might serve as a platform for drug design for CD treatment.
Clinically Distinct Phenotypes of Canavan Disease Correlate with Residual Aspartoacylase Enzyme Activity

Marisa I Mendes,Desirée EC Smith,Ana Pop,Pascal Lennertz,Matilde R Fernandez Ojeda,Warsha A Kanhai,Silvy JM van Dooren,Yair Anikster,Ivo Barić,Caroline Boelen,Jaime Campistol,Lonneke de Boer,Ariana Kariminejad,Hulya Kayserili,Agathe Roubertie,Krijn T Verbruggen,Christine Vianey-Saban,Monique Williams,Gajja S Salomons

DOI: https://doi.org/10.1002/humu.23181

2017-02-14

Human Mutation

Abstract:We describe 14 patients with 12 novel missense mutations in ASPA, the gene causing Canavan disease (CD). We developed a method to study the effect of these 12 variants on the function of aspartoacylase-the hydrolysis of N-acetyl-l-aspartic acid (NAA) to aspartate and acetate. The wild-type ASPA open reading frame (ORF) and the ORFs containing each of the variants were transfected into HEK293 cells. Enzyme activity was determined by incubating cell lysates with NAA and measuring the released aspartic acid by LC-MS/MS. Clinical data were obtained for 11 patients by means of questionnaires. Four patients presented with a non-typical clinical picture or with the milder form of CD, whereas seven presented with severe CD. The mutations found in the mild patients corresponded to the variants with the highest residual enzyme activities, suggesting that this assay can help evaluate unknown variants found in patients with atypical presentation. We have detected a correlation between clinical presentation, enzyme activity, and genotype for CD.

genetics & heredity
[A retrospective evaluation of exposure to dichloromethane by using a job-exposure matrix].

Pierluigi Cocco,Mustafa Dosemeci,Manuel R. Gómez,Heinemann Eh,Patricia A. Stewart,Aaron Blair

Abstract:The impact of three features of a job-exposure matrix has been tested in a case-control study that evaluated the association of occupational exposure to dichloromethane and astrocytic brain cancer. These features were probability of exposure, an exposure assessment by decades, and the use of a more specific coding system of industries and occupations. The introduction of each feature had a striking effect on the estimate of relative risk. The odds ratio increased from 1.47 with none of these features, to 2.47 with high probability of exposure, to 4.15 with high probability of exposure and the specific coding system, to 6.08 with all features combined. These results indicate that job-exposure matrices efficacy in reducing the degree of exposure misclassification may be greatly improved by the introduction of these features.
Evolutionarily conserved chaperone-mediated proteasomal degradation of a disease-linked aspartoacylase variant

Sarah K. Gersing,Yong Wang,Martin Grønbæk-Thygesen,Caroline Kampmeyer,Lene Clausen,Claes Andréasson,Amelie Stein,Kresten Lindorff-Larsen,Rasmus Hartmann-Petersen

DOI: https://doi.org/10.1101/2020.09.04.283028

IF: 4.5

2020-01-01

PLoS Genetics

Abstract:Canavan disease is a severe progressive neurodegenerative disorder that is characterized by swelling and spongy degeneration of brain white matter. The disease is genetically linked to polymorphisms in the aspartoacylase ( ASPA ) gene, including the substitution C152W. ASPA C152W is associated with greatly reduced protein levels in cells, yet biophysical experiments suggest a wild-type like thermal stability. Here, we examine the stability and degradation pathway of ASPA C152W. When we expressed ASPA C152W in Saccharomyces cerevisiae , we found a decreased steady state compared to wild-type ASPA as a result of increased proteasomal degradation. However, molecular dynamics simulations of ASPA C152W did not substantially deviate from wild-type ASPA, indicating that the native state is structurally preserved. Instead, we suggest that the C152W substitution prevents ASPA from reaching its stable native conformation, presumably by impacting on de novo folding. Systematic mapping of the protein quality control components acting on misfolded and aggregation-prone species of C152W, revealed that the degradation is highly dependent on the molecular chaperone Hsp70, its co-chaperone Hsp110 as well as several quality control E3 ubiquitin-protein ligases, including Ubr1. In human cells, ASPA C152W displayed increased proteasomal turnover that was similarly dependent on Hsp70 and Hsp110. We propose that Hsp110 is a potential therapeutic target for misfolding ASPA variants that trigger Canavan disease due to excessive degradation. ### Competing Interest Statement The authors have declared no competing interest.
The pathogenesis of, and pharmacological treatment for, Canavan disease

Huijun Wei,John R Moffett,Man Amanat,Ali Fatemi,Takashi Tsukamoto,Aryan M Namboodiri,Barbara S Slusher

DOI: https://doi.org/10.1016/j.drudis.2022.05.019

Abstract:Canavan disease (CD) is an inherited leukodystrophy resulting from mutations in the gene encoding aspartoacylase (ASPA). ASPA is highly expressed in oligodendrocytes and catalyzes the cleavage of N-acetylaspartate (NAA) to produce aspartate and acetate. In this review, we examine the pathologies and clinical presentation in CD, the metabolism and transportation of NAA in the brain, and the hypothetical mechanisms whereby ASPA deficiency results in dysmyelination and a failure of normal brain development. We also discuss therapeutic options that could be used for the treatment of CD.
Canavan disease: Clinical features and recent advances in research

Hideki Hoshino,Masaya Kubota

DOI: https://doi.org/10.1111/ped.12422

2014-08-01

Pediatrics International

Abstract:Canavan disease (CD) is a genetic neurodegenerative leukodystrophy that results in the spongy degeneration of white matter in the brain. CD is characterized by mutations in the gene encoding aspartoacylase (ASPA), the substrate enzyme that hydrolyzes N-acetylaspartic acid (NAA) to acetate and aspartate. Elevated NAA and subsequent deficiency in acetate associated with this disease cause progressive neurological symptoms, such as macrocephaly, visuocognitive dysfunction, and psychomotor delay. The prevalence of CD is higher among Ashkenazi Jewish people, and several types of mutations have been reported in the gene coding ASPA. Highly elevated NAA is more specific to CD than other leukodystrophies, and an examination of urinary NAA concentration is useful for diagnosing CD. Many researchers are now examining the mechanisms responsible for white matter degeneration or dysmyelination in CD using mouse models, and several persuasive hypotheses have been suggested for the pathophysiology of CD. One is that NAA serves as a water pump; consequently, a disorder in NAA catabolism leads to astrocytic edema. Another hypothesis is that the hydrolyzation of NAA in oligodendrocytes is essential for myelin synthesis through the supply of acetate. Although there is currently no curative therapy for CD, dietary supplements are candidates that may retard the progression of the symptoms associated with CD. Furthermore, gene therapies using viral vectors have been investigated using rat models. These therapies have been found to be tolerable with no severe long-term adverse effects, reduce the elevated NAA in the brain, and may be applied to humans in the future.

pediatrics
Screening for Diabetic Retinopathy

Daniel E. Singer,David M. Nathan,Howard A. Fogel,A. Schachat

DOI: https://doi.org/10.7326/0003-4819-116-8-660

IF: 39.2

1992-04-15

Annals of Internal Medicine

Abstract:PURPOSE To determine the appropriate patients, methods, and timing for screening for diabetic retinopathy. DATA SOURCES Relevant articles were identified through prominent review articles, the authors' files, recommendations from experts, and a MEDLINE search (1986 to the present); additional references were selected from the bibliographies of identified articles. STUDY SELECTION Selection of articles on the natural history of retinopathy was limited to large clinical series and formal epidemiologic studies of defined populations. Selection of articles on the therapeutic effect of photocoagulation and of glycemic control was limited to randomized trials. Sources bearing on the accuracy of screening modalities were necessarily more varied. DATA EXTRACTION For important variables, individual estimates from multiple studies are presented rather than a single meta-analytic summary estimate. RESULTS Screening for retinopathy is justifiable if early detection leads to less vision loss at an acceptable cost. The evidence shows that 1) laser therapy reduces the rate of vision loss by 50% among patients with proliferative retinopathy and macular edema, conditions that are often asymptomatic; 2) duration of diabetes is the main risk factor for retinopathy; and 3) standard ophthalmoscopic examination has only moderate sensitivity (about 80% in research settings) and specificity (greater than 90% for proliferative retinopathy but lower for macular edema), making seven-field stereophotography a more accurate method. Estimates of cost effectiveness indicate that screening for retinopathy not only saves years of vision but may be cost saving from a societal perspective. CONCLUSIONS Screening for retinopathy in patients with diabetes, and subsequent photocoagulation therapy for those who have high risk macular edema or proliferative retinopathy, is clearly beneficial.
Two patients with Canavan disease and structural modeling of a novel mutation

Osama K Zaki,Navaneethakrishnan Krishnamoorthy,Heba S El Abd,Soumaya A Harche,Reem A Mattar,Rana S Al disi,Mariam Y. Nofal,Rajaa El Bekay,Khalid A Ahmed,C George Priya Doss,Hatem Zayed

DOI: https://doi.org/10.1007/s11011-016-9896-9

IF: 3.6551

2016-08-17

Metabolic Brain Disease

Abstract:Canavan disease (CD) is a rare fatal childhood neurological autosomal recessive genetic disease caused by mutations in the ASPA gene, which lead to catalytic deficiency of the ASPA enzyme, which catalyzes the hydrolysis of N-acetyl-L-aspartate (NAA) into aspartate and acetate. CD occurs frequently among Ashkenazi Jewish population, however it has been reported in many other ethnic groups with significantly lower frequency. Here, we report on two Egyptian patients diagnosed with CD, the first patient harbors five missense mutations (c.427 A > G; p. I143V, c.502C > T; p. R168C, c.530 T > C; p. I177T, c.557 T > C; p. V186D c.548C > T; p. P183L) and a silent mutation (c.693 C > T; p. Y231Y). The second patient was found to be homozygous for two missense mutations (c.427 A > G; p. I143V and c.557 T > A; p. V186D). Furthermore, molecular modeling of the novel mutation p. P183L provides an instructive explanation of the mutational impact on the protein structure that can affect the function of the ASPA. Here, the clinical, radiological, and biochemical profile of the two patients are reviewed in details.

neurosciences,endocrinology & metabolism
Images in clinical medicine. Ischemic gangrene.

Zhu Shen,Qi Ye

DOI: https://doi.org/10.1056/NEJMicm1001755

IF: 158.5

2010-12-30

New England Journal of Medicine

Abstract:n engl j med 363;27 nejm.org december 30, 201
Metastatic Renal Cell Carcinoma to the Contralateral Ureter: A Rare Phenomenon

Ashley Dixon,M. Tretiakova,J. Gore,B. Voelzke

DOI: https://doi.org/10.1016/j.eucr.2015.10.005

2015-12-10

Urology Case Reports

Abstract:
A Novel Mutation in Aspartoacylase Gene; Canavan Disease

Mahmoudreza Ashrafi,Alireza Tavasoli,Pegah Katibeh,Omid Aryani,Mohammad Vafaee-Shahi

Abstract:Objective Canavan disease (CD) is a type of vacuolating leukodystrophy with autosomal recessive inheritance. Aspartoacylase deficiency results in decrease of myelin biosynthesis, dysmyelination and brain edema. Although CD is a very common in Ashkenazi Jews patients, several cases have been reported from non-Jewish population. This report is based on a homozygous C.202G>A mutation in the ASPA gene identified from an Iranian patient. To our knowledge, this type of mutation has not been reported in non-Jewish population in the literature.
Clinical and Aspartoacylase Gene Mutation Analysis of Canavan Disease in a Child

Yang Zhigang,Chen Guohong,Yang Yanling,Kang Lulu,Nie Lei

DOI: https://doi.org/10.3760/cma.j.issn.1006-7876.2019.06.009

2019-01-01

Abstract:Objective To investigate the clinical and aspartoacylase (ASPA) gene mutation characteristics of Canavan disease.Methods The clinical data of a child with Canavan disease diagnosed by gene detection who visited Children's Hospital Affiliated to Zhengzhou University in June 2018 were reviewed and analyzed.Results A one year and five months old girl presented with psychomotor retrogression,hypermyotonia,and tendon hyperreflexia.The urinary N-acetylaspartic acid levels were significantly higher (66.832 7,more than 60 times that of normal individuals).Magnetic resonance imaging of the brain showed a multiple and symmetrical hyperintense signal changes in the cerebral white matter.Two heterozygous mutations c.79_80del (p.Gly27Arg) and c.554G＞T (p.Gly185Val) were screened by targeted next generation sequencing.The results of Sanger sequencing showed the two mutations were compound heterozygous mutation derived from her father and mother,and the mutation c.554G＞T has never been reported.Conclusions The next generation sequencing can accurately detect ASPA gene mutation as the first choice for the diagnosis of Canavan disease.The mutation c.554G＞T enriches the gene mutation spectrum of Canavan disease.
A novel Aspartoacylase (ASPA) Gene Mutation in Canavan Disease

Asude Alpman Durmaz,Haluk Akin,Huseyin Onay,Ali Vahabi,Ferda Ozkinay

DOI: https://doi.org/10.3109/15513815.2011.650292

2012-04-02

Fetal and Pediatric Pathology

Abstract:Canavan disease is a severe autosomal recessive leukodystrophy characterized by macrocephaly, ataxia, severe motor and mental retardation, dysmyelination, and progressive spongial atrophy of the brain. The human aspartoacylase (ASPA) gene, which catalyzes the deacetylation of N-acetyl-L-aspartate, is mutated in Canavan disease. In the presented family sequencing analysis for the aspartoacylase gene was performed on the blood samples of the parents as the affected child had died due to Canavan disease. After the mutation was detected, prenatal diagnosis was also performed and heterozygous Y88X mutation was detected in the fetus. In this report, we present a novel mutation Y88X within the aspartoacylase gene in a consanguineous family with an affected child diagnosed as Canavan disease.

pediatrics,pathology
[Hypodense nodular images in the spleen of a patient with human immunodeficiency virus infection].

J. C. Callejas Rubio,M. A. López Ruz,P. García Ruiz,J. Hernández Quero

Abstract:
Canavan Disease: Studies on the Knockout Mouse

Reuben Matalon,Kimberlee Michals-Matalon,Sankar Surendran,Stephen K. Tyring

DOI: https://doi.org/10.1007/0-387-30172-0_6

2024-02-07

Advances in experimental medicine and biology

Abstract:1. AbstractCanavan disease (CD) is an autosomal recessive disorder, characterized by spongy degeneration of the brain. Patients with CD have aspartoacylase (ASPA) deficiency, which results accumulation of N-acetylaspartic acid (NAA) in the brain and elevated excretion of urinary NAA. Clinically, patients with CD have macrocephaly, mental retardation and hypotonia. A knockout mouse for CD which was engineered, also has ASPA deficiency and elevated NAA. Molecular studies of the mouse brain showed abnormal expression of multiple genes in addition to ASPA deficiency. Adenoassociated virus mediated gene transfer and stem cell therapy in the knockout mouse are the latest attempts to alter pathophysiology in the CD mouse.

medicine, research & experimental,biology
NAAG synthetase deficiency has only low influence on pathogenesis in a Canavan disease mouse model

Ivonne Becker,Lihua Wang‐Eckhardt,Matthias Eckhardt

DOI: https://doi.org/10.1002/jimd.12693

IF: 4.7501

2023-11-29

Journal of Inherited Metabolic Disease

Abstract:Canavan disease (CD) is a leukodystrophy caused by mutations in the N‐acetylaspartate (NAA) hydrolase aspartoacylase (ASPA). Inability to degrade NAA and its accumulation in the brain results in spongiform myelin degeneration. NAA is mainly synthesized by neurons, where it is also a precursor of the neuropeptide N‐acetylaspartylglutamate (NAAG). Hydrolysis of this peptide by glutamate carboxypeptidases is an additional source of extracellular NAA besides the instant neuronal release of NAA. This study examines to what extent NAA released from NAAG contributes to NAA accumulation and pathogenesis in the brain of Aspanur7/nur7 mutant mice, an established model of CD. Towards this aim, Aspanur7/nur7 mice with additional deficiencies in NAAG synthetase genes Rimklb and/or Rimkla were generated. Loss of myelin in Aspanur7/nur7 mice was not significantly affected by Rimkla and Rimklb deficiency and there was also no obvious change in the extent of brain vacuolation. Astrogliosis was slightly reduced in the forebrain of Rimkla and Rimklb double deficient Aspanur7/nur7 mice. However, only minor improvements at the behavioral level were found. The brain NAA accumulation in CD mice was, however, not significantly reduced in the absence of NAAG synthesis. In summary, there was only a weak tendency towards reduced pathogenic symptoms in Aspanur7/nur7 mice deficient in NAAG synthesis. Therefore, we conclude that NAAG metabolism has little influence on NAA accumulation in Aspanur7/nur7 mice and development of pathological symptoms in CD.

genetics & heredity,endocrinology & metabolism,medicine, research & experimental
Association Between SCN5A R225Q Variant and Dilated Cardiomyopathy: Potential Role of Intracellular Ph and WNT/β-catenin Pathway

Jingjing Hu,Kun Yang,Yongchao Zhao,Zilun Wei,Lebing Yang,Rifeng Gao,Yonghui Wu,Lei Xu,Sujuan Xu,Kai Hu,Aijun Sun,Junbo Ge

DOI: https://doi.org/10.1136/jmedgenet-2021-108396

2022-01-01

Journal of Medical Genetics

Abstract:BackgroundThe SCN5A variant is a common cause of familial dilated cardiomyopathy (DCM). We previously reported a SCN5A variant (c.674G>A), located in the high-risk S4 segment of domain I (DI-S4) region in patients with idiopathic DCM and R225Q knockin (p.R225Q) mice carrying the c.674G>A variant exhibited prolonged baseline PR intervals without DCM phenotypes. In this study, we explored the association and mechanism between R225Q variant and DCM phenotype.MethodsPrevalence of DI-S4 variant was compared between patients with idiopathic DCM and the control participants. R225Q knockin and wild-type (WT) mice were subjected to doxorubicin (DOX), D-galactose (D-gal) or D-gal combined with DOX.ResultsClinical data suggested that the prevalence of DI-S4 variant was higher in DCM group than in the control group (4/90 (4.4%) vs 3/1339 (0.2%), p<0.001). Cardiomyocytes from R225Q knockin mice treated with D-gal and DOX exhibited more significant hypertrophic phenotype and weaker contraction/dilation function and an increased level of apoptosis as compared with WT mice. Mechanistically, we found that R225Q variant could increase intracellular pH and further induce the activation of the WNT/β-catenin pathway as well as the overexpression of pro-hypertrophic and pro-apoptotic targets. WNT-C59 inhibitor improved cardiac function in the R225Q knockin mice treated with D-gal and DOX.ConclusionOur results suggest that R225Q variant is associated with increased susceptibility to DCM. Ageing could enhance this process via activating WNT/β-catenin signaling in response to increased intracellular pH. Antagonising the WNT/β-catenin pathway might be a potential therapeutic strategy for mitigating R225Q variant-related DCM pathogenesis.
Identification of potential pharmacological chaperones that selectively stabilize mutated Aspartoacylases in Canavan disease

Nitesh Kumar Poddar,Yasanandana S Wijayasinghe,Ronald E Viola

DOI: https://doi.org/10.1016/j.bbapap.2024.141043

2024-08-09

Abstract:Canavan disease is caused by mutations in the ASPA gene, leading to diminished catalytic activity of aspartoacylase in the brain. Clinical missense mutations are found throughout the enzyme structure, with many of these mutated enzymes having not only decreased activity but also compromised stability. High-throughput screening of a small molecule library has identified several compounds that significantly increase the thermal stability of the E285A mutant enzyme, the most predominant clinical mutation in Canavan disease, while having a negligible effect on the native enzyme. Based on the initial successes, some structural analogs of these initial hits were selected for further examination. Glutathione, NAAG and patulin were each confirmed to be competitive inhibitors, indicating the binding of these compounds at the dimer interface or near the active site of the E285A enzyme. The experimental results were theoretically examined with the help of the docking analysis method. The structure activity-guided optimization of these compounds can potentially lead to potential pharmacological chaperones that could alleviate the detrimental effect of ASPA mutations in Canavan patients.

Anticancer activity of a ceramide analog containing a disulfide linkage.

Maternal lung growth in surgically reduced litter size pregnancy.

Cellular and molecular mechanisms of aspartoacylase and its role in Canavan disease

Comparative computational assessment of the pathogenicity of mutations in the Aspartoacylase enzyme

Clinically Distinct Phenotypes of Canavan Disease Correlate with Residual Aspartoacylase Enzyme Activity

[A retrospective evaluation of exposure to dichloromethane by using a job-exposure matrix].

Evolutionarily conserved chaperone-mediated proteasomal degradation of a disease-linked aspartoacylase variant

The pathogenesis of, and pharmacological treatment for, Canavan disease

Canavan disease: Clinical features and recent advances in research

Screening for Diabetic Retinopathy

Two patients with Canavan disease and structural modeling of a novel mutation

Images in clinical medicine. Ischemic gangrene.

Metastatic Renal Cell Carcinoma to the Contralateral Ureter: A Rare Phenomenon

A Novel Mutation in Aspartoacylase Gene; Canavan Disease

Clinical and Aspartoacylase Gene Mutation Analysis of Canavan Disease in a Child

A novel Aspartoacylase (ASPA) Gene Mutation in Canavan Disease

[Hypodense nodular images in the spleen of a patient with human immunodeficiency virus infection].

Canavan Disease: Studies on the Knockout Mouse

NAAG synthetase deficiency has only low influence on pathogenesis in a Canavan disease mouse model

Association Between SCN5A R225Q Variant and Dilated Cardiomyopathy: Potential Role of Intracellular Ph and WNT/β-catenin Pathway

Identification of potential pharmacological chaperones that selectively stabilize mutated Aspartoacylases in Canavan disease